{"nctId":"NCT03735121","briefTitle":"A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer","startDateStruct":{"date":"2018-12-14","type":"ACTUAL"},"conditions":["Non-Small Cell Lung Cancer"],"count":438,"armGroups":[{"label":"Atezolizumab (Part 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab"]},{"label":"Cohort 1: Atezolizumab+rHuPH20 (Part 1)","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab","Drug: rHuPH20"]},{"label":"Cohort 2: Atezolizumab+rHuPH20 (Part 1)","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab","Drug: rHuPH20"]},{"label":"Cohort 3: Atezolizumab+rHuPH20(Part 1)","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab","Drug: rHuPH20"]},{"label":"Atezolizumab + rHuPH20 (Part 2)","type":"EXPERIMENTAL","interventionNames":["Drug: Atezolizumab","Drug: rHuPH20"]}],"interventions":[{"name":"Atezolizumab","otherNames":["Tecentriq"]},{"name":"rHuPH20","otherNames":["ENHANZE"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Histologically or cytologically documented locally advanced or metastatic NSCLC\n* Prior platinum-containing regimen or disease recurrence ≤ 6 months since prior platinum-based adjuvant/neoadjuvant regimen.\n* Measurable disease as defined by RECIST v1.1\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1\n* Life expectancy ≥12 weeks\n* Adequate hematologic and end-organ function\n\nAdditional Inclusion Criteria (Part 2 Only) • Availability of tissue and known epidermal growth factor receptor (EGFR) status\n\nExclusion Criteria:\n\n* Symptomatic, untreated, or actively progressing central nervous system (CNS) metastases\n* Uncontrolled or symptomatic hypercalcemia\n* Pregnancy or breastfeeding\n* Active or history of autoimmune disease or immune deficiency\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis\n* Severe infection ≤ 4 weeks\n* Treatment with therapeutic oral or IV antibiotics ≤ 2 weeks prior to study treatment\n* Significant cardiovascular disease\n* Prior allogeneic stem cell or solid organ transplantation\n* Treatment with a live, attenuated vaccine ≤ 4 weeks\n* Treatment with systemic immunostimulatory agents ≤ 4 weeks or 5 half-lives of the drug\n* Treatment with systemic immunosuppressive medication ≤ 2 weeks\n\nAdditional Exclusion Criteria (Part 2 Only)\n\n• Tested tumor programmed death-ligand-1 (PD-L1) expression status with an intention to treat the patient if positive","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Part 1: Serum Trough Concentration (Ctrough) of Atezolizumab at Cycle 1","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"121","spread":"42.8"},{"groupId":"OG001","value":"77.5","spread":"51.4"},{"groupId":"OG002","value":"78.3","spread":"88.6"}]}]}]},{"type":"PRIMARY","title":"Part 2: Observed Serum Ctrough of Atezolizumab at Cycle 1","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.4","spread":"34.1"},{"groupId":"OG001","value":"89.4","spread":"127.1"}]}]}]},{"type":"PRIMARY","title":"Part 2: Area Under the Concentration-Time Curve From Time Zero to 21 Days (AUC 0-21 d) at Cycle 1","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3327.9","spread":"19.4"},{"groupId":"OG001","value":"2907.1","spread":"35.9"}]}]}]},{"type":"SECONDARY","title":"Part 1: Maximum Observed Serum Concentration (Cmax) of Atezolizumab","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"251","spread":"40.9"},{"groupId":"OG001","value":"129","spread":"42.5"},{"groupId":"OG002","value":"181","spread":"38.3"}]}]}]},{"type":"SECONDARY","title":"Part 1: Time to Maximum Serum Concentration (Tmax) of Atezolizumab","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.02","spread":null},{"groupId":"OG001","value":"3.45","spread":null},{"groupId":"OG002","value":"3.92","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 1: Area Under the Concentration-time Curve (AUClast) of Atezolizumab","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3870","spread":"38.6"},{"groupId":"OG001","value":"1410","spread":"41.8"},{"groupId":"OG002","value":"2820","spread":"38.6"}]}]}]},{"type":"SECONDARY","title":"Part 1: Serum Atezolizumab Concentration at Specified Timepoint During SC Administration","description":"Cycle length =21 days for cohorts 1 and 3 and 14 days for cohort 2. Day=D; Cycle=C.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"NA","spread":"NA"},{"groupId":"OG001","value":"NA","spread":"NA"},{"groupId":"OG002","value":"NA","spread":"NA"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"116","spread":"57.8"},{"groupId":"OG001","value":"61.7","spread":"70.9"},{"groupId":"OG002","value":"108","spread":"57.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"247","spread":"40.5"},{"groupId":"OG001","value":"123","spread":"44.3"},{"groupId":"OG002","value":"166","spread":"45.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"230","spread":"36.6"},{"groupId":"OG001","value":"110","spread":"45.0"},{"groupId":"OG002","value":"162","spread":"43.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"77.5","spread":"51.4"},{"groupId":"OG002","value":"78.3","spread":"88.6"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"87.7","spread":"64.7"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"183","spread":"46.1"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"245","spread":"42.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG002","value":"225","spread":"37.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"104","spread":"47.8"},{"groupId":"OG002","value":"123","spread":"57.2"}]}]},{"categories":[{"measurements":[{"groupId":"OG001","value":"189","spread":"NA"}]}]}]},{"type":"SECONDARY","title":"Part 1: Percentage of Participants With Adverse Events (AEs)","description":"An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100","spread":null},{"groupId":"OG001","value":"86.7","spread":null},{"groupId":"OG002","value":"79.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With AEs","description":"An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 5.0 (NCI-CTCAE, v5.0).","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Model Predicted Ctrough of Atezolizumab at Cycle 1","description":null,"paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":"26.2"},{"groupId":"OG001","value":"97.2","spread":"42.3"}]}]}]},{"type":"SECONDARY","title":"Part 2: Model Predicted Ctrough at Steady State (Cthrough,ss) of Atezolizumab","description":"1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo.","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"179","spread":"38.8"},{"groupId":"OG001","value":"205","spread":"58.1"}]}]}]},{"type":"SECONDARY","title":"Part 2: Model Predicted AUC at Steady State (AUCss) of Atezolizumab","description":"1 cycle=21 days Abbreviations used-Cycle=C; Day =D; Atezolizumab=atezo","paramType":"GEOMETRIC_MEAN","dispersionType":"Geometric Coefficient of Variation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6107","spread":"27.3"},{"groupId":"OG001","value":"6163","spread":"46.7"}]}]}]},{"type":"SECONDARY","title":"Part 2: Objective Response Rate (ORR)","description":"ORR is defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v) 1.1. CR is the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \\< 10 millimeters (mm). PR is defined as at least a 30% decrease in the sum of diameters (SOD) of target lesions, taking as reference the Baseline sum diameters in the absence of CR.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Progression-Free Survival (PFS)","description":"PFS is defined as the time from study start to the first occurrence of disease progression as determined by the investigator according to RECIST v1.1 or or death from any cause (whichever occurs first).","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Overall Survival (OS)","description":"OS defined as the time from study entry to death from any cause.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Duration of Response (DOR)","description":"DOR is defined as the time from first occurrence of a documented objective response to disease progression as determined by the investigator according to RECIST v1.1. or death from any cause, whichever occurs first. Objective response is defined as the percentage of participants having a CR or PR as determined by investigator assessment of radiographic disease per RECIST v1.1. CR is the disappearance of all target lesions and any pathological lymph nodes must have reduction in short axis to \\< 10 mm. PR is defined as at least a 30% decrease in the SOD of target lesions, taking as reference the Baseline sum diameters in the absence of CR.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Functioning and Global Health Status Over Time, as Assessed by European Organization for Research and Treatment of Cancer (EORTC) Item Library (IL)57","description":"EORTC IL57 questionnaire has10 items and covers 3 scales: physical functioning (PF), role functioning (RF) \\& global health status/quality of life (GHS/QoL) \\& 1 item from EORTC Item Library. PF scale has 5 items evaluating the extent to which participants have trouble doing strenuous activities; taking long walks \\& short walks; need to stay in bed or a chair; need help with eating, dressing, bathing/using toilet. RF scale has 2 items evaluating extent to which participants are limited in doing work \\& pursuing leisure activities in previous week. GHS/QoL scale has 2 items evaluating participants' overall health \\& QoL in previous week. Questions are answered on a 4-point Likert scale (where 1=\"Not at all\" to 4=\"Very much\") for physical and role functioning \\& a 7-point scale (where 1=\"Very poor\" to 7=\"Excellent\") for GHS/QoL. For each scale, mean of the items are linearly transformed to obtain scores from 0-100, where 100 =best possible score. Higher score = better outcome.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Overall Satisfaction With Treatment Over Time, Assessed by the Modified Satisfaction With Therapy (SWT) Scale of the Cancer Therapy Satisfaction Questionnaire (CTSQ)","description":"Modified SWT scale of the CTSQ consist of seven items that measures seven domains related to satisfaction with cancer therapy. These include worthwhile, difficulty, benefits, feelings about side effects, form of therapy, overall satisfaction, and if participants would choose the therapy taking everything into consideration. Each domain is rated on a 5-point scale, with 1 representing the worst response and 5 representing the best response, except in the case of one reverse-scored item. mean of the items are linearly transformed to obtain scores from 0-100, where 100 =best possible score Higher scores are associated with higher satisfaction.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Overall Patient-reported AE's Burden Over Time, Assessed by the Treatment-related Symptom Burden Item From the EORTC IL57","description":"The overall patient-reported AE burden was assessed using the a single item from the EORTC IL57 questionnaire i.e To what extent have you been troubled with side-effects from your treatment?. The questions is answered on a 4-point Likert scale where 1=\"Not at all\" to 4=\"Very much\". Higher scores indicates greater AE burden.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With Ant-Drug Antibodies (ADAs) to Atezolizumab After SC or IV Administration","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Percentage of Participants With ADAs to rHuPH20 After SC Administration Relative to the Prevalence of ADAs at Baseline","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Convenience, Potential Time Savings, and Overall Satisfaction With Atezolizumab SC Compared With Atezolizumab IV as Assessed by the Health Care Professional (HCP) SC Versus IV Perspective Questionnaire","description":"The HCP Subcutaneous Versus IV Perspective Questionnaire consists of five items evaluating the number of atezolizumab SC and IV administrations done, convenience, potential time savings, and overall satisfaction with atezolizumab SC and atezolizumab IV, as well as reasons for HCP-reported satisfaction or dissatisfaction.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Part 2: Convenience, Ease of Administration, and Overall Satisfaction With Atezolizumab SC Assessed Using HCP Subcutaneous Perspective Questionnaire","description":"The HCP Subcutaneous Perspective Questionnaire consists of five items evaluating the convenience, ease of administration and overall satisfaction with atezolizumab SC, as well as reasons for HCP-reported satisfaction or dissatisfaction.","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":13},"commonTop":["Anaemia","Fatigue","Decreased Appetite","Cough","Dyspnoea"]}}}